Filing Flows › Industries › Health Care › Surgical & Medical Instruments & Apparatus
Surgical & Medical Instruments & Apparatus SIC 3841
114 companies filing with the SEC under SIC 3841. Median revenue growth +10% year on year in Q3 2026 (middle half +3% to +17%, 58 companies). The growth model expects the industry's combined revenue to grow +7% in Q3 2026. 22 customer or supplier links named in annual reports.
Money flow: where the industry's revenue goes
Drawn in the browser: an estimate of where the industry's revenue goes — what it buys from other industries, the pay that reaches households, taxes and profit — beside its filed cash flow, two tiers of suppliers and its capital spending by kind of asset.
Open the industry: growth distribution, money flow, network →
Who sells to whom
Customers and suppliers named in the companies' annual reports; the share is of the supplier's revenue.
- ITGR → BSX 49% of the supplier's revenue, $908M
- IRTC → Medicare & Medicaid 24% of the supplier's revenue, $179M
- UFPT → ISRG 22% of the supplier's revenue, $130M
- MDXG → U.S. government 22% of the supplier's revenue, $92.1M
- TCMD → Medicare & Medicaid 51% of the supplier's revenue, $80.5M
- ANIK → JNJ 50% of the supplier's revenue, $56.4M
- RVP → U.S. government 54% of the supplier's revenue, $34.6M
- IDXG → Medicare & Medicaid 27% of the supplier's revenue, $10.4M
- CLPT → PTCT 15% of the supplier's revenue, $5.5M
- EMBC → COR
- EMBC → MCK
- EMBC → CAH
- GE → PREM
- NDAQ → OSRH
- ICUI → INFU 60% of the supplier's revenue
- ICUI → LQDA
- AMZN → HTFL
- SANM → OBIO
- MDAI → U.S. government
- AAPL → DRIO
- UFPT → SYK
- GOOGL → DRIO
Growth model
Industry revenue, the same companies year on year; 80% ranges. Fitted on SEC filings and tested out of sample (how).
| Quarter | Growth Y/Y | Revenue | 80% range |
|---|---|---|---|
| Q3 2026 | +7.4% | $50.4B | $46.9B – $54.0B |
| Q4 2026 | +8.5% | $53.3B | $49.1B – $57.5B |
| Q1 2027 | +8.8% | $50.0B | $46.0B – $54.1B |
| Q2 2027 | +8.6% | $53.3B | $48.9B – $57.6B |
Capital spending and supply chain →
Companies
| Company | Quarterly revenue | Y/Y | Stage |
|---|---|---|---|
| MDLN Medline | $7.9B | +10% | transition |
| MMM 3M | $6.6B | +1% | mature |
| SYK Stryker | $6.5B | +8% | mature |
| BSX Boston Scientific | $5.1B | +1% | deceleration |
| BDX Becton Dickinson | $5.0B | — | mature |
| BAX Baxter International | $3.0B | +5% | mature |
| SOLV Solventum | $1.9B | -7% | contraction |
| RMD ResMed | $1.4B | +6% | mature |
| DXCM DexCom | $1.3B | +11% | transition |
| WST West Pharmaceutical Services | $874M | +9% | deceleration |
| MMED MiniMed Group | $843M | — | transition |
| PODD Insulet | $842M | +19% | deceleration |
| GMED Globus Medical | $764M | -0.7% | mature |
| TFX Teleflex | $568M | -38% | contraction |
| ICUI ICU Medical | $560M | +4% | mature |
| MMSI Merit Medical Systems | $416M | +8% | mature |
| IART Integra Lifesciences Holdings | $411M | +2% | mature |
| PEN Penumbra | $410M | +16% | transition |
| HAE Haemonetics | $358M | +9% | mature |
| TNDM Tandem Diabetes Care | $284M | +14% | reacceleration |
| EMBC Embecta | $272M | — | mature |
| IRTC iRhythm Holdings | $222M | +15% | deceleration |
| ATEC Alphatec Holdings | $221M | +13% | transition |
| GKOS Glaukos | $211M | +58% | expansion |
| OFIX Orthofix Medical | $211M | — | mature |
| INSP Inspire Medical Systems | $207M | -8% | contraction |
| NVCR NovoCure | $193M | +16% | transition |
| UFPT UFP Technologies | $172M | +12% | transition |
| ATRC AtriCure | $154M | +15% | transition |
| BVS Bioventus | $142M | +3% | mature |
| AORT Artivion | $124M | +9% | mature |
| PRCT Procept BioRobotics | $98.3M | +18% | transition |
| TCMD Tactile Systems Technology | $91.9M | +7% | mature |
| ARAY Accuray | $86.5M | -8% | mature |
| ANGO Angiodynamics | $80.9M | +7% | mature |
| KIDS Orthopediatrics | $72.7M | +19% | expansion |
| SKIN SkinHealth Systems | $69.2M | -2% | mature |
| LMAT Lemaitre Vascular | $68.0M | +11% | transition |
| HTFL Heartflow | $64.1M | — | expansion |
| MDXG Mimedx Group | $62.3M | -45% | contraction |
| CERS Cerus | $57.7M | +10% | mature |
| SIBN Si-Bone | $55.7M | +14% | transition |
| TMCI Treace Medical Concepts | $48.3M | -4% | mature |
| STIM Neuronetics | $42.0M | +13% | transition |
| INFU InfuSystem Holdings | $37.6M | +3% | mature |
| BBNX Beta Bionics | $35.5M | +30% | deceleration |
| KMTS Kestra Medical Technologies | $31.0M | — | deceleration |
| OSUR Orasure Technologies | $30.6M | — | mature |
| ANIK Anika Therapeutics | $30.6M | +10% | deceleration |
| DCTH Delcath Systems | $29.1M | — | deceleration |
| RCEL Avita Medical | $26.1M | +53% | expansion |
| SGHT Sight Sciences | $24.9M | +25% | expansion |
| IRMD Iradimed | $24.2M | +14% | reacceleration |
| XTNT Xtant Medical Holdings | $23.0M | — | transition |
| LUNG Pulmonx | $22.8M | +6% | mature |
| NPCE NeuroPace | $22.8M | — | mature |
| PDEX Pro DEX | $20.6M | +11% | deceleration |
| TELA Tela Bio | $19.3M | — | mature |
| CARL Carlsmed | $18.9M | — | transition |
| LNSR Lensar | $16.5M | — | reacceleration |
Growth from positive, comparable quarterly revenue as filed; industries are SEC Standard Industrial Classification codes. Data Nov 8, 2026.